AGP Executive Report
Last update: 36 minutes agoClinical Trial Update: The LiBBY trial presented at AAIC reports that a THC/CBD oral combo (2 mg THC + 100 mg CBD) reduced agitation in hospice-eligible dementia patients, a group often left out of prior studies. Regulatory & Policy: Minnesota’s Office of Cannabis Management chief is holding a community Q&A in Mankato as adult-use sales expand; in Virginia, an Op-Ed says new recovery residence rules still force medical cannabis patients to choose between treatment and housing. Federal Rescheduling Fight: MMJ International highlights what it calls a contradiction in DEA rescheduling proceedings, arguing the agency blocked its participation while later testimony addressed the same factual gap. Public Health & Safety: A Hopkinton board adopted rules banning kratom and synthetic THC product sales; a study also links cannabis use with reduced opioid withdrawal-related opioid use. Industry Politics: Major cannabis firms donated millions to Trump-aligned PACs, underscoring a lobbying push across marijuana, hemp, and alcohol interests. Youth Use Signals: A large U.S. study finds substance experimentation rises sharply by mid-adolescence, with girls surpassing boys around age 13.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[THC/CBD Combination Cuts Agitation in Hospice-Eligible Dementia: LiBBY Trial]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26978646-929361567-92b25d8649127e50e9de5b21b5adcaa250a0ceb2-1200x628-100x52.png)
